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INTRODUCTION 
Studies from Europe and the USA have shown that 
infective endocarditis (IE) has an incidence of 2-4 per 
100 000 person years in the general population. In the 
USA, the direct medical costs involved in the treatment 
of this infection have been estimated to be $100 million 
annually Among the various factors contributing to 
these costs, the hospital length of stay is undoubtedly 
one of the most important. Thus, one day of intra- 
venous antibiotics has been recently estimated to cost 
$700-1200 when given in hospital, as compared to 
$200-300 for outpatient administration [I]. Since 
the need for parenteral antibiotics is often the main 
reason for prolonged hospitalization, efforts have been 
directed at using shorter courses of antibiotic therapy 
or at administering the antibiotics on an outpatient 
basis (outpatient antibiotic therapy (OPAT)). These 
approaches are certainly strongly encouraged by 
economic incentives, not to mention other obvious 
advantages which are welcomed by most of the 
patients, such as earlier return to home and work, as 
well as less injections with some regimens [2,3]. 
Economic considerations are especially important in 
developing countries [4]. 
Even though home intravenous therapy is theoret- 
ically possible with any antibiotic regimen, recent 
advances have considerably facilitated this approach. 
Corresponding author and reprint requests: 
Patrick B. Francioli, Hygiene Hospitaliere, CHUV, 
BH 19 Rue de Buguau, 1012 Lausanne, Switzerland 
Tel: +41 21 314 02 52 Fax: +41 21 314 02 62 
E-mail: Patrick.Francioli@chuv.hospvd.ch 
Certain antibiotics with long half-lives may be 
administered with a single daily injection [5]. More- 
over, there is experimental and clinical evidence that 
synergism between 6-lactams and aminoglycosides can 
be obtained with a single daily administration of the 
aminoglycoside, thus allowing shorter courses of 
treatment [6-91. Thus various antibiotic regimens may 
offer convenient therapeutic options for OPAT of 
endocarditis. Finally, in the future, the good oral 
bioavailability of certain compounds, such as quino- 
lones, may allow partial or total oral outpatient 
antibiotic treatment of selected patients [10,11], but this 
approach needs to be carefully assessed by good clinical 
studies. 
There is no prospective study comparing inpatient 
treatment to partial or total OPAT of IE. O n  the other 
hand, there are no data demonstrating that hospital- 
ization improves outcome or limits the likelihood of 
complications such as emboli or rupture of rnyotic 
aneurysm. Several studies have shown that selected 
patients can safely receive partial or total OPAT 
[5,8,12]. A survey among infectious disease specialists 
in the USA has shown that most of them had already 
used this approach [3], and IE accounts for some of the 
cases reported by various OPAT programs [13]. 
In a recently published study, Dimayuga and 
Brown reviewed their experience with OPAT in 
endocarditis: of 85 patients with IE seen between 1986 
and 1993, 39 received a portion of their treatment as 
outpatients, among whom 56% were infected with 
penicillin-susceptible streptococci and 44% with 
staphylococci or enterococci [14]. Four patients had 
*The group of experts comprised: D.T. Durack, C. Leport and 
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Table 1 Risks associated with outpatient treatment of 1E and measures to minimize them [2\ 
Risk Measure 
Sudden complications 
Iklay in diagnosis of complicat~ons 
Initiation of treatment in hospital 
Easy access to medical care ifproblems 
Selection of patients 
Arterid embolism 
Cardiac failure Hrmodynd~nically stable 
Kuptui-e of niycotic anrurym~ 
Vegetations of <1 cii1 
No Tymptoms suggestive of inycotlc aneuryml? 
I’roblriii~ with iiifraveiious h i e  Prefer interniittent intravenous rnfuslons or intramuscular injections 
Intravenous therapy service 
Hazards linked to activities requirins prrmanrnt dttcnrion 
Coinpliancc 
Avoidance (e.g. driving) 
Appropriate individual and social conditmns 
prosthetic valve endocarditis. Some of thein had 
presented it1-hospital complications before being sent 
home for completion of the antibiotic treatment (four 
metastatic abscesses, four neurologic events, nine 
congestive heart failure and seven surgical valve 
replacement). At the time ofdischarge, all patients were 
medically stable and had been afebrile for at  least 3 days. 
During the post-discharge period, two relapses were 
observed and one late embolus. No death was recorded 
at  6-month follow-up. In these 39 patients, 68% of the 
days of antibiotic therapy were outpatient days. This 
study, combined with others, clearly suggests that 
OPAT can be successfully and safely used in many 
patients with IE involving native or even prosthetic 
valves, regardless of the pathogen, provided that these 
patients are carefully selected. 
RISKS IN PATIENTS WITH INFECTIVE 
ENDOCARDITIS 
Various aspects should be considered with respect to 
potential problems which may occur during OPAT of 
endocarditis [2,31. Risks should be carefully evaluated 
and measures should be taken to minimize theni (Table 
1). 
Congestive heart failure 
Although hemodynamic deterioration may occur in 
any patient, this is more likely to affect patients with 
left-sided endocarditis and with some degree of heart 
failure on adniission (21. Therefore, careful evaluation 
of cardiac function should allow the selection of 
patients at low risk for the development of cardiac 
insufficiency during out-patient treatment. Thiy selec- 
tion can be based on clinical and echocardiographic 
findings. Patients wirh premature closure of the niitral 
valve, ruptured niitral valve chordae, torn aortic cusps 
or large vegetations are at  increased risk for the 
development of cardiac failure, and should probably be 
kept in hospital for a certain period to ensure that they 
are hernodynamically stable. Other cardiac compli- 
cations, such as myocardial infarct or sudden death 
caused by occlusion of the coronary arteries by 
vegetations, are only rare complications of streptococcal 
IE. Right-sided endocarditis is generally well tolerated 
from the hemodynamic point of view. 
Emboli 
Arterial embolus is the second most coninion complic- 
ation of IE and is a Inajor concern in all patients with 
endocarditis, especially left-sided endocarditis. Should 
wch an event occur, it is probably preferable that it 
happens while the patient is in hospital, although this 
might not change the ultimate prognosis. Emboli 
mostly occur before or within the first few days after 
initiation of appropriate antibiotic therapy. In one 
study, the incidence of embolic events fell from 13 per 
1000 patient days during the first week of antimicrobial 
therapy to fewer than 1.2 per 1000 patient-days after 2 
weeks of therapy [ 151. Moreover, emboli are less 
frequent in streptococcal endocarditis than in endo- 
carditis due to more virulent microorganisms [I 51. 
These data suggest that,  after a few days of treatment, 
patients with streptococcal endocarditis are at  relatively 
low risk of emboli. Systemic emboli are very rare in 
right-sided endocarditis and should therefore not be a 
problem. However, pulmonary enibolisnis in these 
patients may represent a major clinical feature and 
should be well under control before OPAT is con- 
sidered 19,111. 
Echocardiography 
The role of echocardiography in predicting the risk of 
systemic embolization in left-sided endocarditis is 
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controversial. Vegetations ofa size that can be visualized 
by transthoracic echocardiography (TTE) are detected 
in 70-80% of cases when using two-dimensional 
imaging. Transesophageal echocardiography (TEE) has 
been reported as detecting vegetations in up to 96% of 
cases of proven endocarditis [ 16,171. Many reports 
suggest that, in patients with endocarditis. vegetations 
detected by TTE are associated with a higher risk of 
embolization. In a composite of 11 studies, the risk was 
36% with echocardiographically demonstrated vegeta- 
tions and 15% when echocardiograms were normal 
[18]. In a study which used both TTE and TEE, 
patients who had a large vegetation (>lo mm) had a 
significantly higher incidence of embolic events (47%) 
than those with small or no vegetations (19%) [16]. 
Because an embolic event may reduce the size of 
vegetations, the analysis was also made after exclusion 
of the patients who had echocardiography after the 
embolic episode; the rate of new embolism was 36% in 
patients with large vegetations as compared to 6% in 
those with small vegetations, a difference which was 
also significant. The average size of the vegetations of 
the patients who presented with an embolic episode 
after echocardiography was greater than that of patients 
without embolism. Patients with a ‘mobile’ vegetation 
had a significantly higher incidence of embolic episodes 
than patients with a ‘sessile’ vegetation, but this was not 
an independent variable because most of the patients 
with a large vegetation also had a mobile vegetation. In 
contrast, mobile vegetations were seen in less than 50% 
of those with a small vegetation. When subgroups of 
patients were analyzed, only those with mitral involve- 
ment were at  increased risk for emboli based on the 
vegetation size. Similar findings were reported in a large 
study analyzing 204 patients [19]. However, some 
recent studies did not show a relationship between the 
size of the vegetations and the occurrence of emboli: 
in a study which analyzed embolic events after the 
onset of effective antimicrobial therapy in 207 patients 
with left-sided native valve endocarditis, there was no 
statistically significant difference in the incidence rate 
of emboli among patients with definite vegetations 
compared to those with absent or indeterminate 
vegetations, and patients with vegetations larger than 
10 mm in diameter did not have an increased rate of 
emboli, either with aortic or with mitral valve 
involvement [ 151. 
Since echocardiography findings do not permit the 
reliable prediction or exclusion of embolic events in a 
given patient, some clinicians feel that patients should 
not be disqualified from OPAT based solely on the 
demonstration of valvular vegetations seen on 
echocardiography. However, as discussed above, several 
studies suggest that vegetations seen on echocardio- 
graphy, especially those >I0  mm, are associated with a 
higher risk of embolism, particularly in patients with 
mitral valve infection. The presence of large vegetations 
has also been associated with an increased risk of heart 
failure. Therefore, OPAT should be considered more 
cautiously and should probably not be initiated during 
the first 2 weeks of antibiotic therapy in patients with 
large, mobile vegetations, especially when they affect 
the mitral valve. 
Mycotic aneurysms 
Ruptured mycotic aneurysms constitute a major 
complication of endocarditis. Although they can occur 
without warning signs, many patients experience some 
symptoms hours or even days before rupture, such as 
severe headache, visual disturbances or cranial nerve 
palsy [20]. Patients selected for OPAT should be told 
to report promptly in case of any clinical manifestation. 
Mycotic aneurysms are very rare in right-sided 
endocarditis. 
Intravenous line complications 
Risks linked to the intravenous administration of 
antibiotics depend on the type ofvenous access. In cases 
where prolonged catheterization is required, phlebitis, 
catheter infection or catheter-related bacteremia may 
all occur, as in the hospital setting, and the same 
preventive measures should be applied. The patient 
should be given adequate information, and should 
know what to do in case of a local, systemic or technical 
problem. 
SELECTION OF THE PATIENTS AND OPTIONS 
FOR ANTIBIOTIC DELIVERY 
A number of conditions should be fulfilled for the 
optimal management of IE. A ‘team approach’ is 
important, and close collaboration between the 
infectious diseases physician, the microbiologist, the 
cardiologist, the cardiac surgeon, the nurses and the 
general practitioner in charge of the patient is 
mandatory. Depending on the setting and antibiotic 
used, a pharmacist should be included [21]. For OPAT, 
other prerequisites are medical stability of the patient 
(absence of fever, well-controlled congestive heart 
failure or absence of congestive heart failure), low risk 
of complications, and adequate medical and social 
environment allowing good compliance, surveillance 
and follow-up. The patient should have appropriate 
insurance cover (Table 2). If OPAT is considered to be 
feasible for a given patient, there are several options for 
the organization of the antibiotic delivery and the 
choice will be determined by the local situation (Table 
3 ) .  The type of venous access will depend on various 
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Table 2 Outpatient pareriteral antiblotlc therapy: selection 
of uaticnts 
ECONOMIC ASPECTS 
Medical conditions of the patient 
Physical and mental abilities 
Co-morbidities 
Stability 
Risk of coniplications 
Williiigne~s 
Gcneral coiitcxt 
Transportation 
Telephone 
Access to hoypital 
Faiiilly support 
Inwrance cover 
Table 3 Outpatient parenteral antibiotic therapy: options 
for antibiotic deliverv 
~ 
Srtt111g 
Infusion ccnter 
Outpaticnt clinic 
Ckneral physician’s officc 
Visiting nursc 
Self-ddiniiiistrdtion 
Vcnous acccss 
Direct intravenour (lntrainuscular) administration 
Short infusion with a butterfly needle (heparin lock o r  daily 
Peripheral or central carhrter (locked or oprn) 
POI-t 
placement) 
Pumps 
Like any outpatient treatment, OPAT of IE has some 
economic incentives and disincentives [2,3]. The point 
of view on this issue depends on whom one considers: 
the patient, the hospital, the physician in charge or the 
third-party payers. For the patient, an earlier return to 
home and productive work as well as less family travel 
to and from hospital are strong incentives, but this may 
result in additional out-of-pocket costs and a need for 
travel to and from medical facilities. For the hospital, 
incentives depend on the type o f  payment. With 
prospective payment, OPAT will result in lower costs 
but constant reimbursement, and also in possible 
additional revenues from outpatient clinics. With per 
diem reimbursement, OPAT will result in loss of 
revenues for the period of treatment during which costs 
are likely to be low because the work-up is finished and 
complications are less likely to occur. For the physician, 
OPAT will probably imply increased administrative 
work and increased risk of litigation, and there might 
be less financial compensation. Finally, for third-party 
payers, OPAT will result in cost savings even if there is 
full reimbursement of direct costs. Thus, the 
viewpoints of all the partners should be taken into 
consideration when one considers OPAT. 
INFORMATION 
factors: venous status of the patient, projected length 
of treatment, pharniacokinetic properties of the 
antibiotic, potential for phlebitis of the drug, and 
preference of the patient. If once-daily administration 
of antibiotic(s) is contemplated, direct intravenous 
injection or short infusion through a butterfly needle 
may be chosen. Intramuscular injection is another 
possibility with some of the antibiotics. Both routes can 
be combined on an alternate basis. In some patients, 
the venous access can be maintained with a heparin 
lock of a butterfly needle or of a peripheral catheter. 
For patients with difficult venous access, a permanent 
intravenous catheter or a port can be considered. For 
antibiotic regimens complicated enough to require 
several daily administratiom, a pump system and a 
durable catheter can be implanted. This is probably not 
necessary with the regimens proposed in the present 
article. However, if the prerequisites for outpatient 
therapy are met, as outlined above, patients with IE due 
to any type of microorganism can potentially be eligible 
for OPAT, and in some cases the administration of an 
antibiotic regimen which requires several daily 
administrations may be warranted. 
Patient understanding of all aspects of the disease and 
its management is important. Patients should probably 
be advised to avoid activities requiring permanent 
attention (driving a car, etc.) while on intravenous 
antibiotic treatment, for reasons of safety and possible 
litigation in case of  problems. 
ANTIBIOTIC REGIMENS FOR OUTPATIENT 
TREATMENT OF VlRlDANS STREPTOCOCCAL AND 
STREPTOCOCCUS BOYIS ENDOCARDITIS 
Patients eligible for OPAT or for short courses of 
conibinations of antibiotics are primarily those with 
subacute presentation and no complications. In 
addition, some patients, such as drug addicts, are 
reluctant to stay in hospital and demand alternative 
management. In this article, we will mainly review the 
antibiotic regimens of viridans streptococcal endo- 
carditis and of staphylococcal right-sided endocarditis 
in drug addicts. 
Penicillin-susceptible strains 
There are several antibiotic therapy options for the 
treatment of viridans streptoccocal and Streptococcus booi5 
endocarditis which have been validated by clinical 
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Table 4 Selected studes of antibiotic regimens suitable for out-patient treatment of penicillin-susceptible viridans 
streptococcus and S. bovis endocardltis 
Antibiotic Duration Results Remarks References 
Ceftriaxone 
Ceftriaxone 
versus 
Ceftriaxone 
+ 
Amoxycillin 
Cefiriwone 
Aminoglycoside 
+ 
Ceftriaxone 
versus 
Ceftriaxone 
+ 
Gentatmcin 
Teicoplanin 
q.d. 
q.d. 
q.d. 
q i d .  
q.d. 
q.d. 
q.d. 
q.d. 
q.d. 
q.d. 
4 weeks 
4 weeks 
2 weeks 
2 weeks 
+ 
2 weeks 
4 weeks 
2 weeks 
2 weeks 
4 weeks 
q.d., once daily; q.i.d., four times a day. 
55 patients 
No bacteriologic failure 
10 valve replacement 
No death 
27 patients with no  permanent 5 
intravenous catheter 
39% of cases discharged after <2 weeks 
15 patients 
15 patients 
1 clinical relapse 
No failure 
No death 
52 patients 
1 bacteriologic failure 
7 valve replacement 
5 deaths (non-infectious) 
23 patients 
22 bacteriologic cure 
4 valve replacement 
21 patients 
20 bacteriologic cure 
4 valve replacement 
20 patients 
10 with complete course 
1 microbiological fallure 
23% of cases treated as outpatient 12 
67% treated both as in- and outpatient 
380 days of hospitalization ‘saved for 
30 cases 
4 cases with increased creatinine 
(all >65 years and with renal risk factors) 
5 cases treated only as outpatient. 
10 cases treated as in- and outpatient 
Out of 672 days of therapy, 124 were 
outpatient days 
8 
Mild side effects in both groups 23 
2 cases of increased creatinine in the 
gentamicin group 
5 courses interrupted because of drug fever 24 
studies [22 ] .  Some of them are more suitable than 
others for OPAT because of the pharmacokinetic 
properties of the compounds, which allow once- or 
twice-daily administration of the antibiotic(s) (Table 4). 
Ceftriaxone for 4 weeks 
Ceftriaxone sodium has a half-life of 6-9 h and 
excellent activity against a wide variety of micro- 
organisms, including streptococci and bacteria from the 
HACEK group [2]. In the rabbit model of viridans 
streptococcal endocarditis, ceftriaxone was found to be 
equal in efficacy as procaine penicillin [25]. To date, 
there have been three published studies on the 
treatment of streptococcal endocarditis by ceftriaxone 
alone or in combination with other antibiotics, and an 
additional study has been presented as an abstract [23]. 
In a European non-comparative multicenter trial, 
59 adult patients with streptococcal endocarditis were 
treated with ceftriaxone sodium administered at a 
once-daily dose of 2 g for 4 weeks [ 5 ] .  Treatment was 
completely uneventful in 42 patients (71%). A cardiac 
valve replacement was performed in 10 patients (16%). 
Valves taken at surgery were sterile. No relapse was 
observed. Emboli developed in five patients during 
therapy, leading to valve replacement in two patients, 
already mentioned above. One patient died suddenly 
without clinical evidence of infection 3 months after 
completing therapy. The most worrisome side effect 
was reversible neutropenia attributed to ceftriaxone, 
which was observed in three patients. Ceftriaxone 
could be administered in many patients without a 
permanent indwelling intravenous catheter, through 
the daily placement of a butterfly needle either as a 
short infusion or as a direct slow intravenous injection. 
Twenty-seven patients (46%) had no permanent 
indwelling catheter at any time, and seven (12%) had 
the line for less than 4 days. In the other 21 patients, 
the line was maintained for more than 4 days either 
because of the intravenous administration of other 
medications or because the initial catheter was well 
tolerated and the physicians decided to maintain it for 
the administration of ceftriaxone. In seven patients, 
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treatment was administered partially or totally by 
intramuscular injections. For these patients, 2 g of 
ceftriaxone was mixed with 4.5-5 mL of lidocaine, and 
injected into the gluteal muscles. In some patients, the 
volume was divided and injected simultaneously at  two 
different sites. Intramuscular injections were well 
tolerated. 
Although no effort was made to select patients who 
would possibly qualify for outpatient treatment, 23 of 
the 59 patients (39%) could be discharged from the 
hospital after less than 2 weeks. In these cases, the drug 
was administered either in the outpatient clinics of the 
participating hospitals or in the private physician's 
office. It  is worth mentioning that seven patients had 
to stay in hospital for the entire course of treatment 
only because of inappropriate outpatient settings. 
In a $tudy performed in Argentina [I 21, 30 patients 
with clinical diagnoric of endocarditis and blood 
cultures positive for penicillin-susceptible streptococci 
were randomized to receive either a 4-week course of 
one daily dose of ceftriaxone (2 g IV or IM) or a 
2-week course of ceftriaxone as above, followed by oral 
anioxycillin (1 g four times a day) for 2 additional 
weeks. Patients with coniplications were excluded. All 
patients had a prompt clinical response, with defer- 
vescence in the first 24-48 h in all but one patient. 
Heart failure and central nervous system complications 
each occurred in one patient. This low rate of 
complications was probably related to the criteria used 
for the selection of the patients. One probable relapse 
occurred in one patient 3 months after treatment with 
ceftriaxone for 4 weeks, but blood culture remained 
negative. Ceftriaxone was administered by intravenous 
injection to 12 of 30 patients, by intramuscular 
injection to 10 and by intravenous or intramuscular 
injection to eight. Pain at  the injection sites was 
reported by some patients but did not necessitate 
discontinuation of therapy; no  complications were 
noted at the intramuscular injection sites. Moreover, a 
high dose of oral amoxycillin was successfully sub- 
stituted for ceftriaxone during the last 2 weeks of 
therapy in compliant patients who demonstrated serum 
bactericidal titers above 1:8 (about half of the patients). 
In this study, cases with obvious complications were 
excluded, so that a larger proportion of the cases could 
be treated as outpatients. Seven patients (23%) were 
treated entirely as outpatients, and 20 (67%) received 
both inpatient and outpatient treatment. The authors 
calculated that 380 days of hospitalization had been 
saved for these 27 patients, using, for the calculation, 
an average hospital stay of 20 days for patients treated 
by standard regimens with penicillin. Additional savings 
could be generated with a switch to oral amoxycillin 
after 14 days, but such an approach deserves further 
studies, keeping in mind that oral amoxycillin alone for 
the entire course of treatment has been associated with 
high failure rates. 
Ceftriaxone plus aminoglycoside for 2 weeks 
The efficacy of a 2-week regimen of high-dose 
penicillin combined with two or three daily doses of a n  
aminoglycoside is well established [26]. However, it is 
not an optimal regimen for outpatient therapy because 
it requires several daily adniinistratioris of both 
antibiotics. Because the in vitro and in vivo activities of 
ceftriaxone against streptococci are similar to those of 
penicillins, a combination of ceftriaxone with an 
aniinoglycoside administered for 2 weeks should also be 
effective. Moreover, recent data have suggested that the 
administration of the total daily amount of an 
aminoglycoside in one dose is as effective and possibly 
less toxic than two or three equally divided doses in the 
treatment of various infections. In endocarditis, this 
concept is supported by experiniental data [6,7]. 
Two recent studies have tested the efficacy of a 14- 
day course of ceftriaxone combined with an aniino- 
glycoside, both administered in a single daily dose 
18,231. 
The first study is a multicenter non-comparative 
trial of ceftriaxone combined with netilinicin, both 
administered as a single daily injection [ 8 ] .  Among 52 
patients (viridans streptococci 3 1,  S. bovis 18, Crruiella 
vnorbillovcrm two, group C streptococcus one), 48 were 
assessable, 42 were cured (35 with niedical and seven 
with combined medical and surgical treatment), five 
died but without evidence of active infection, and one 
relapsed. The bacteriologic failure was due to a strain 
of 6. vnorbillovum for which no synergism could be 
demonstrated in vitro. In four patients, all above 65 
years and with renal risk factors, an increase in serum 
creatinine value was observed during treatment which 
did not return to baseline during follow-up in two of 
them. Among 40 patients who could be assessed for 
auditory function, one developed a decreased percep- 
tion of borderline significance. Other side effects were 
mild. In 25 patients, the entire treatment was 
administered by the daily placement of a butterfly 
needle. Five patients were treated as out patients and 10 
as in and out patienty. 
In the second study, ceftriaxone alone for 4 weeks 
was conipared to once-daily administration of ceftri- 
axone plus gentamicin 1231. Preliminary results suggest 
that the two regimens are equivalent, but two cases of 
increased creatinine were observed in the gentamicin 
arm. 
Thus, a 2-week course of-a single daily administra- 
tion of ceftriaxone plus an aminoglycoside appears to 
be an efficacious, safe and cost-effective alternative to 
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other antibiotic regimens for streptococcal endo- 
carditis, but this regimen should be used with caution 
in patients with pre-existing renal or ear impairment, 
or in those exposed concomitantly to other potentially 
oro- or nephrotoxic agents. Moreover, it should not 
be given to patients with complications such as 
estracardiac foci of infections or myocardial abscess, 
which would require a more prolonged course of treat- 
ment. 
In summary, these studies suggest that ceftriaxone 
for 4 weeks or ceftriaxone and an aminoglycoside for 
2 weeks, administered once daily, are effective and 
safe regimens for penicillin-susceptible streptococcal 
endocarditis, with a cure rate comparable to that 
obtained with penicillin. In hospitals, ceftriaxone is 
more convenient to administer than penicillin with or 
without aminoglycoside. Moreover, it allows partial 
or total outpatient treatment of a substantial number 
of patients. Short regimens are not recommended 
for patients at risk for aminoglycoside toxicity or for 
patients with certain complications [22]. 
Teicoplanin for 4 weeks 
Another convenient option for parenteral outpatient 
treatment of streptococcal endocarditis with one-daily 
injection might be provided by teicoplanin, a glyco- 
peptide which also has a long half-life and good in vitro 
activity against streptococci. However, good, large 
studies have not been done, and some results have been 
disappointing. Thus, in one study which included 20 
patients, only 10 completed a 4-week course of 
teicoplanin (500 mg every 12 h on the first 2 days and 
then 10 mg/kg every 24 h): nine were cured but one 
relapsed [24]. Among the other 10 patients, five (25%) 
experienced drug fever which prompted treatment 
interruption. Other suboptimal experience with 
teicoplanin in the treatment of endocarditis has been 
reported [27]. Thus, teicoplanin deserves further 
investigation before it can be recommended as an 
alternative once-daily parenteral regimen for the 
treatment of streptococcal endocarditis. It should 
probably be restricted to patients with immediate 
penicilllin allergy. Should it be used, it is crucial that 
adequate doses are given [22]. 
Penicillin-resistant, nutritionally deficient strains 
For patients who are infected with relatively penicillin- 
resistant or nutritionally deficient streptococcal strains, 
current recommendations include a 4-week penicillin 
regimen with gentamicin added at least during the first 
2 weeks [22]. For strains with intermediate suscept- 
ibility to penicillin and ceftriaxone (<0.5 mg/L), 
ceftriaxone can probably be substituted for penicillin. 
For strains with MICs greater than 0.5 mg/L and for 
nutritionally variant streptoccoci, a standard regimen 
for enteroccocal endocarditis is recommended [22]. 
ANTIBIOTIC REGIMENS FOR RIGHT-SIDED 
STAPHYLOCOCCUS A UREUS END 0 CARD lTlS 
Right-sided Staphylococcus aureus endocarditis in drug 
addicts often has a rather benign course. Moreover, 
poor compliance and lack of adequate insurance cover 
of many of these patients are problems. This has 
stimulated interest in short-course combination 
therapy, treatment with parenteral antibiotics with long 
half-lives, and oral treatment (Table 5). 
Short-course combination therapy 
The data on 2-week courses of antibiotic therapy 
for right-sided endocarditis have recently been 
reviewed [9]. Most published studies have used a 
combination of a semisynthetic penicillin admin- 
istered at a dose of 1.5-2 g every 4 h, and an 
aminoglycoside injected in two or three divided 
doses. Among a total of 134 episodes treated with 
these regimens, one death, one clinical failure and 
three relapses were recorded. 
Because there is no comparative study showing 
that short-course combination therapy is as safe 
and effective as standard regimens of longer duration, 
only carefully selected patients should be treated with 
this approach. Moreover, regimens including a 
semisynthetic penicillin require several administra- 
tions per day and are not very convenient for 
OPAT. 
Teicoplanin 
Because of its long half-life and good in vitro activity 
against staphylococci, teicoplanin would be an attrac- 
tive antibiotic for outpatient treatment of staphylo- 
coccal endocarditis. However, clinical failures have 
been recorded in as many as 20% of patients with left- 
sided endocarditis, and side effects requiring the 
interruption of treatment are frequent [27,29]. In a 
recent comparative study, four clinical failures with 
three breakthrough bacteremias developed among eight 
patients with right-sided endocarditis who received 
teicoplanin [28]. Thus, teicoplanin must be used with 
caution for this indication at  this point. Should it be 
considered, adequate dosages are of utmost importance 
[22,30]. 
Oral regimens 
Because fluoroquinolones are reasonably well absorbed 
orally at  doses that cause few side effects, and because 
of their good in vitro activity against susceptible 
staphylococci, oral regimens to treat selected cases of 
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Table 5 Treatment options for selected patients with right-sided staphylococcal endocarditis 
Antibiotic Duration Results References 
Senu-synthetic penicillin 
+ 
Ariiinoglycoside 
Teicoplanin 
Ciprofloxacin 
Kifainpicin 
+ 
Ciprofloxacin 
+ 
Kifainpicin 
vrrsw 
Oxacillin (Vancoinycin) 
Gentainicin 
+ 
2 weeks 
4 weeks 
4 weeks 
4 weeks 
134 episodes (3 studies) 
1 clinical failure 
3 bacteriologic falures 
1 death 
8 patients 
4 clinical failures including 
3 breakthrough bacterernia 
10 assessable patient$ 
No failure 
29 episodes 
3 clinical failures 
I bacteriologic failure 
1 drug failure 
30 episodes 
3 clinical and bacteriologic failures 
19 drug toxicity 
9 
28 
10 
11 
endocarditis can be envisioned. In order to reduce the 
likelihood of emergence of resistance, fluoroquinolones 
have been used in combination with rifampicin. This 
niay also result in a synergism, although conflicting 
results have been observed. 
In a limited clinical trial, ciprofloxacin 750 mg 
twice 3 day and rifampicin 300 mg twice a day 
(administered intravenously for the first 5-7 days) for 4 
weeks was successful in 10 patients with right-sided 
endocarditis [ 101. In another study, ciprofloxacin plus 
rifampicin administered orally was compared to 
oxacillin (or vancomycin) plus gentamicin. The two 
regimens were equivalent in terms of efficacy but there 
were more side effects in the oxacillin-gentamicin 
group [ I t ] .  
Thus, oral regimens for patients with right-sided 
endocarditis appear to offer a good alternative to 
intravenous treatment. I t  is important to emphasize that 
patients with complications were excluded from these 
studies. Thus only selected patients are eligible for this 
approach 19,311. Compliance with antibiotic treatment 
is certainly an important problem in intravenous drug 
users with right-sided endocarditis. Even though oral 
antibiotic regimens are promsing in this indication, 
some authors prefer short-course intravenous therapy 
with a combination of agents administered in hospital. 
CONCLUSIONS 
Various antibiotic regimens allow outpatient treatment 
of endocarditis due to viridans streptococci or 
staphylococci (right-sided endocarditis). As suggested 
by several studies, this therapeutic strategy is feasible. 
Selection of patients at  low risk for complications and 
eligible for outpatient therapy requires careful 
evaluation [2]. However, sudden or rapidly progressing 
complications during therapy might occur even in 
carefully selected patients. Therefore, easy and rapid 
access to medical facilities where appropriate investig- 
ation and surgical intervention can be performed 
proinptly is a prerequisite for outpatient therapy, at least 
in developed countries. Moreover, an appropriate social 
environment is important, in case the patient needs 
help to gain access to medical care. The patient should 
probably refrain from certain activities requiring con- 
stant attention (e.g. driving) in order to avoid potential 
life-threatening hazards to himself or other people, 
should a sudden event occur during treatment. 
For non-compliant patients, a short regimen with 
a combination of antibiotics administered in the 
hospital is probably preferable to outpatient therapy. 
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